Contents
CVS Caremark agreed to pay $36.7 million in a ranitidine Medicaid settlement to resolve allegations that it switched patients from tablets to more expensive capsules to increase Medicaid reimbursement. A licensed pharmacist brought the whistleblower case. If you know why a pharmacy changed the version of a drug it dispensed, your account connects a routine prescription to a payment decision the claim alone does not explain.
The Justice Department announced the settlement on March 18, 2008, covering alleged switching from 2000 through 2006. It identified ranitidine as generic Zantac and said CVS Caremark operated more than 6,000 retail pharmacies nationwide at the time of the announcement.
This page follows the retail dispensing decision and the resulting payment, a provider-fraud allegation. Caremark’s Quantum Leap settlement in 2013 and RxCLAIM settlement in 2014 concerned reimbursements owed back to Medicaid: allegedly canceled reimbursement claims in one platform and improper copayment or deductible reductions in the other.
The Justice Department’s Illinois example put the alleged switching incentive into a single prescription. From December 15, 2000, through April 1, 2001, the department said CVS Caremark charged Illinois Medicaid about $80 for 60 ranitidine capsules instead of about $17 for the tablets.
The Justice Department alleged that the switch provided no additional medical benefit to patients. We see a remarkable upgrade in that allegation: the capsule improved the reimbursement.
For a pharmacist, the distinction starts with the dosage form. Both versions carried the ranitidine name, but the Justice Department’s account turned on the choice between tablets and capsules and the much higher reimbursement attached to the latter. Someone who knows the prescription and the dispensing decision can explain what a drug name by itself leaves out.
Medicaid combines federal and state funding, and each state’s plan sets out the services it buys and how providers get paid. That makes the state and the period part of the payment story. We connect a pharmacy’s product choice to the reimbursement that applied to that prescription.
In the ranitidine allegation, the more expensive version was the product dispensed. The Justice Department said CVS Caremark used that choice to substantially increase Medicaid reimbursement. The question for an insider is what explains the switch: how the choice was made, what staff understood about it, and how the higher payment figured in the decision.
That account has a clinical side and a payment side. A pharmacist may understand why a particular dosage form was used, while someone in billing or pharmacy operations may understand the reimbursement attached to it. We bring those accounts together around the same prescription, so the product decision and the public money can be understood together.
The licensed pharmacist who brought the CVS case occupied a position where product knowledge mattered. The allegation connected the version dispensed, the reimbursement and the absence of an additional medical benefit. For a pharmacy insider, the useful detail may be the reason for the switch, including instructions or explanations that never appear as a separate item on a bill.
A study of healthcare fraud controls explains why that inside account can matter. Health Care Fraud Control: Understanding the Challenge, published in the Journal of Insurance Medicine in 1996, found that claims-processing checks corrected billing errors and rejected ineligible claims while accepting the underlying information as true. The paper distinguished checking whether a claim qualified for payment from checking whether its account of care was true. It put the problem sharply:
One of the surprising truths of the fraud control business is that fraud works best when claims processing works perfectly.
Health Care Fraud Control: Understanding the Challenge, Journal of Insurance Medicine, 1996
Applied to a dispensing allegation, that observation directs attention to the choice behind the bill. A system can calculate payment for a capsule without explaining why the patient was switched to it. In the CVS allegation, the product changed and the payment rose, while the patient received no additional medical benefit. A pharmacist who understands the reason for that product choice brings a different kind of knowledge from a system that prices the product entered.
Connecting the records poses a separate problem. In 2012, the Journal of Information Systems Applied Research published Applying Business Intelligence Concepts to Medicaid Claim Fraud Detection, an exploratory Nevada study of incontinence-supply claims. Its data linked provider, facility and prescription-claim transactions, but arrived from three payer organizations in three different formats. The paper explained that records designed for payment and care delivery had to be reshaped for fraud analysis.
For a pharmacy billing insider, that distinction matters when a dispensing record and a payment record describe different parts of the same transaction. Knowing how the entries fit together helps us connect the product chosen to the amount Medicaid paid and the decision behind it.
The announced federal share of the CVS settlement was approximately $21.1 million. Twenty-three states and the District of Columbia were to share $15.6 million under separate settlement agreements. The U.S. Attorney’s Office in Chicago supervised the joint federal and state health care fraud investigation.
CVS Caremark also entered a compliance agreement with the Department of Health and Human Services aimed at preventing improper drug switching in the future. The announcement said that agreement would remain in effect for five years.
The announcement said the licensed pharmacist would receive about $4.3 million as a whistleblower reward from the federal and state settlements. A whistleblower case under the False Claims Act can pay 15% to 30% of what the government recovers.
If you know who directed a drug switch or how the reimbursement influenced it, speak with our whistleblower experts about the dispensing decision. We build your account into a case strategy and bring in Medicaid pharmacy fraud whistleblower lawyers who understand the connection between the prescription and the payment. We stay alongside you from the first call, pursuing the strongest case your evidence supports.